Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial

S Stintzing; B Price; L Knight; A McCavigan; S Walker; P Harkin; R Kennedy; Daniel Neureiter; S Held; A Jung; T Kirchner; V Heinemann

Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial

S Stintzing, B Price, L Knight, A McCavigan, S Walker, P Harkin, R Kennedy, Daniel Neureiter, S Held, A Jung, T Kirchner, V Heinemann

Institute of Pathology

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	ANNALS OF ONCOLOGY
Volume	28
Publication status	Published - 2017
Event	42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, SPAIN Duration: 8 Sept 2017 → 12 Sept 2017

Cite this

Stintzing, S., Price, B., Knight, L., McCavigan, A., Walker, S., Harkin, P., Kennedy, R., Neureiter, D., Held, S., Jung, A., Kirchner, T., & Heinemann, V. (2017). Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial. ANNALS OF ONCOLOGY , 28.

Stintzing, S ; Price, B ; Knight, L et al. / Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial. In: ANNALS OF ONCOLOGY 2017 ; Vol. 28.

@article{2edbb8da21d842c0a3d7a3149213b163,

title = "Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial",

author = "S Stintzing and B Price and L Knight and A McCavigan and S Walker and P Harkin and R Kennedy and Daniel Neureiter and S Held and A Jung and T Kirchner and V Heinemann",

year = "2017",

language = "English",

volume = "28",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "42nd European-Society-for-Medical-Oncology Congress (ESMO) ; Conference date: 08-09-2017 Through 12-09-2017",

}

Stintzing, S, Price, B, Knight, L, McCavigan, A, Walker, S, Harkin, P, Kennedy, R, Neureiter, D, Held, S, Jung, A, Kirchner, T & Heinemann, V 2017, 'Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial', ANNALS OF ONCOLOGY , vol. 28.

Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial. / Stintzing, S; Price, B; Knight, L et al.
In: ANNALS OF ONCOLOGY , Vol. 28, 2017.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial

AU - Stintzing, S

AU - Price, B

AU - Knight, L

AU - McCavigan, A

AU - Walker, S

AU - Harkin, P

AU - Kennedy, R

AU - Neureiter, Daniel

AU - Held, S

AU - Jung, A

AU - Kirchner, T

AU - Heinemann, V

PY - 2017

Y1 - 2017

M3 - Abstract (Journal)

SN - 0923-7534

VL - 28

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - 42nd European-Society-for-Medical-Oncology Congress (ESMO)

Y2 - 8 September 2017 through 12 September 2017

ER -

Stintzing S, Price B, Knight L, McCavigan A, Walker S, Harkin P et al. Predictive assay for anti-angiogenic agents (AADx) identifies molecular subgroups of RASwt mCRC with differential efficacy of FOLFIRI plus bevacizumab in the FIRE-3 (AIO KRK-0306) trial. ANNALS OF ONCOLOGY . 2017;28.